



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

CIN : L74899DL1978PLC009181

JPL/SEC/RESU-NOT1

Date : November 10th, 2015

To, The National Stock Exchange of India Ltd. Exchange Plaza, Bandara-Kurla Complex Bandra (E), Mumbai - 400 051. Ph. 022-26598452	To, The Bombay Stock Exchange Limited Pherozebhoj Jeejeebhoy Tower Dalal Street, Mumbai - 400 001 Ph. 022-22721234
---	---


SUB: UN-AUDITED FINANCIAL RESULTS FOR QUARTER / HALF YEAR ENDED 30.09.2015 & AUDITOR'S REPORT ON FINANCIAL RESULTS. (LIMITED REVIEW)

Dear Sir,

In terms of Clause 41 of the listing agreement we are sending herewith un-audited financial results for the quarter / half year ended 30th September, 2015 and Auditor's Report on Financial Results. (Limited Review)

Thanking you.

Yours faithfully,
for **JAGSONPAL PHARMACEUTICALS LIMITED**


R K KAPOOR
COMPLIANCE OFFICER CUM COMPANY SECRETARY

Encl. : As above.



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

CIN No:- L74899DL1978PLC009181

Unaudited Financial Results for the Quarter / Half year ended 30.09.2015

Rs. in lacs

Particulars	3 months ended 30.09.2015 Unaudited	3 months ended 30.06.2015 Unaudited	3 months ended 30.09.2014 Unaudited	6 Months ended 30.09.2015 Unaudited	6 Months ended 30.09.2014 Unaudited	12 Months Ended 31.03.2015 Audited
1 Income from operations						
a Net sales/Income from Operations (Net of excise duty)	3296.86	3698.85	3296.06	6995.71	6687.37	13815.09
b Other Operating Income	30.94	0.00	0.00	30.94	0.00	0.00
Total Income from operations (net)	3327.80	3698.85	3296.06	7026.65	6687.37	13815.09
2 Expenses						
a Cost of materials consumed	2164.71	1310.02	1993.77	3474.73	2855.39	6383.36
b Purchases of stock-in-trade	267.62	117.40	347.08	385.02	556.71	649.48
c Changes in inventories of finished goods, work in progress	-1147.36	507.09	-859.78	-640.27	-394.94	-164.55
d Employee benefits expenses	967.46	823.60	754.60	1791.06	1649.58	3211.33
e Depreciation and amortisation expense	73.08	69.14	71.81	142.22	142.90	270.69
f Other expenses	825.27	687.92	813.35	1513.19	1484.02	2862.86
Total expenses	3150.78	3515.17	3120.83	6665.95	6293.66	13213.17
3 Profit from Operations before Other Income, Finance Cost and Exceptional items (1-2)	177.02	183.68	175.23	360.70	393.71	601.92
4 Other Income	3.41	2.90	2.03	6.31	5.14	11.10
5 Profit from ordinary activities before finance cost and Exceptional items (3+4)	180.43	186.58	177.26	367.01	398.85	613.02
6 Finance Cost	120.68	123.33	107.54	244.01	228.15	445.85
7 Profit from ordinary activities after finance cost but before Exceptional Items (5-6)	59.75	63.25	69.72	123.00	170.70	167.17
8 Exceptional Items						
9 Profit/(+)/Loss(-) from Ordinary Activities before tax (7+8)	59.75	63.25	69.72	123.00	170.70	167.17
10 Tax expense	15.90	16.70	33.00	32.60	63.00	50.06
11 Net Profit/(Loss-) from Ordinary Activities after tax (9-10)	43.85	46.55	36.72	90.40	107.70	117.11
12 Extraordinary items (net of tax expense Rs. lacs)						
13 Net Profit/(+)/Loss(-) for the period(11-12)	43.85	46.55	36.72	90.40	107.70	117.11
14 Share of profit/(Loss) of associates						
15 Minority interest						
16 Net Profit/(Loss) after taxes, minority interest and share of	43.85	46.55	36.72	90.40	107.70	117.11
17 Paid up Eq. Sh. Cap.(Face value Rs. 5)	1309.90	1309.90	1309.90	1309.90	1309.90	1309.90
18 Reserves excluding Revaluation reserves as per Balance sheet of pr. Accounting yr						7448.74
19.i Earnings Per Share (before extraordinary items)						
a. Basic (Rs.)	0.17	0.18	0.14	0.35	0.41	0.45
b. Diluted (Rs.)	0.17	0.18	0.14	0.35	0.41	0.45
19.ii Earnings Per Share (after extraordinary items)						
a. Basic (Rs.)	0.17	0.18	0.14	0.35	0.41	0.45
b. Diluted (Rs.)	0.17	0.18	0.14	0.35	0.41	0.45
A PARTICULARS OF SHAREHOLDING						
1 Public Shareholding						
- Number of shares	8076680	8076680	8076680	8076680	8076680	8076680
- Percentage of Shareholding	30.83%	30.83%	30.83%	30.83%	30.83%	30.83%
2 Promoter and promoter group shareholding						
A Pledged / encumbered						
- Number of shares						
- Percentage of shares (as a % of the total shareholding of Promoter and promoter group)						
- Percentage of shares (as a % of the total share capital of the Company)						
B Non - encumbered						
- Number of shares	18121320	18121320	18121320	18121320	18121320	18121320
- Percentage of shares (as a % of the total shareholding of Promoter and promoter group)	100%	100%	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the Company)	69.17%	69.17%	69.17%	69.17%	69.17%	69.17%
B INVESTOR COMPLAINTS						
Pending at the beginning of the quarter	0					
Received during the quarter	25					
Disposed of during the quarter	25					
Remaining unresolved at the end of the quarter	0					

Notes

- The Unaudited Financial Results for the Quarter / Half Year ended 30.9.2015 have been reviewed by the Audit Committee. The Board of Directors has approved the financial Results at its meeting held on 10.11.2015
- The Company is operating only in the Pharmaceuticals segment and hence compliance has been made under AS-17.
- The net effect of the deferred taxation for the Quarter as per AS-22 has been taken.
- Previous year figures have been regrouped / rearranged wherever necessary.

By Order of the Board
For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar
Managing Director
DIN No 00059492

Place : New Delhi
Date : 10.11.2015



Factory : 20 K.M. Mathura Road, Post Office Amar Nagar, Faridabad-121003 (India) Phone : 0091-95129-2275952, 2275953
Factory : Plot No. 14, 15, 16, 55, 56, 57, Sector-5, IIE, Pant Nagar, Rudrapur (U.S. Nagar) - 263153 Uttara Khand

CIN No. L74899DL1978PLC009181

Rs. In lacs

for Jagson Patel Pharmaceuticals Limited

Managing Director

LIMITED REVIEW REPORT FOR

**The Board of Directors
Jagsonpal Pharmaceuticals Limited**

We have reviewed the accompanying statement of unaudited financial results of Jagsonpal Pharmaceuticals Limited for the Quarter / Half year ended 30.09.2015, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been reviewed by us. This statement is the responsibility of the Company's Management and has been approved by Audit Committee and Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, engagements to "Review of Interim Financial Information Performed Independent Auditor of the entity" by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the applicable Accounting Standards specified under Section 133 of the Companies Act 2013, read with rule 7 of the Companies (Accounts) rule, 2014 and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For P. P. THUKRAL & CO.,
Chartered Accountants**

**Place : New Delhi
Date : 10.11.2015**




**SURESH SETHI
PARTNER
F.R. No. 000632 N
Membership no. 89318**